March 28, 2018 News by Jose Marques Lopes, PhD Flex Pharma’s MS Treatment Candidate FLX-787 Improves Cramps, Stiffness, Phase 2 Trial Shows Topline results of an exploratory Phase 2 clinical trial revealed that Flex Pharma‘s treatment candidate FLX-787 improvesĀ muscle cramps, spasms and muscle stiffness in patients with multiple sclerosis (MS). The double-blinded trial, conducted in Australia, evaluated an oral dose of 19 mg FLX-787, taken twice daily in liquid…
November 30, 2017 News by Patricia Silva, PhD Flex Pharma Completes Patient Enrollment in Phase 2 Trial of Muscle-relaxing Compound Flex Pharma has completed enrolling multiple sclerosis patients in a Phase 2 clinical trial in Australia testing FLX-787’s ability to alleviate muscle stiffness, spasms, and cramps. The compound has a mechanism of action that Flex believe will generate fewer side effects than other muscle-relaxing medications. The company is also…
January 26, 2017 News by Patricia Silva, PhD Flex Pharma Shifts Focus to Programs Targeting MS, Other Neurological Diseases Flex PharmaĀ said it plans toĀ prioritize developing its clinical programs in neurological diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies like Charcot-Marie Tooth (CMT). One or two proof-of-concept, Phase 2 clinical trials are planned for this year in the United States to evaluate Flex Pharmaās…
June 20, 2016 News by Patricia Silva, PhD Phase 2 Study to Evaluate an Oral Drug to Treat MS-related Spasticity and Cramps Flex Pharma, Inc., announced the start of aĀ Phase 2Ā clinical trialĀ assessing the safety and efficacy ofĀ FLX-787 in multiple sclerosis (MS) patients who suffer fromĀ cramps, spasms, and/or spasticity as a result of the disease. The trialĀ is being run in conjunction withĀ Neuroscience Trials Australia. Flex Pharmaās FLX-787 is aĀ single molecule,…
October 21, 2015 News by Patricia Silva, PhD Flex Pharma Presenting Data on Promising Muscle Cramp Therapeutic Agent FLX-787 at Neuroscience 2015 Flex Pharma, Inc., a biotechnology company focused on therapies for muscle cramps and spasms associated with neuromuscular conditions, recently announced that it will present new data on its therapeutic agent FLX-787 at the 2015 Annual Meeting of the Society for Neuroscience, currently taking place in Chicago (October 17ā21).
November 17, 2014 News by Maureen Newman Limb Spasm Treatments for MS Patients Explored by Flex Pharma and Ipsen Biopharmaceuticals Upper limb spasticity and lower leg cramps and spasms, two conditions that affect patients with multiple sclerosis, are being treated in separate clinical trials with results from both showing positive benefits. Dysport (abobotulinumtoxinA), from Ipsen Biopharmaceuticals, Inc., and transient receptor potential (TRP) activators, from…